Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, Canada.
Curr Opin Microbiol. 2013 Oct;16(5):566-72. doi: 10.1016/j.mib.2013.07.010. Epub 2013 Aug 10.
Novel classes of antimicrobials are needed to address the challenge of multidrug-resistant bacteria. Current bacterial drug targets mainly consist of specific proteins or subsets of proteins without regard for either how these targets are integrated in cellular networks or how they may interact with host proteins. However, proteins rarely act in isolation, and the majority of biological processes are dependent on interactions with other proteins. Consequently, protein-protein interaction (PPI) networks offer a realm of unexplored potential for next-generation drug targets. In this review, we argue that the architecture of bacterial or host-pathogen protein interactomes can provide invaluable insights for the identification of novel antibacterial drug targets.
需要新型的抗菌药物来应对抗药性细菌的挑战。目前的细菌药物靶点主要包括特定的蛋白质或蛋白质亚群,而不考虑这些靶点在细胞网络中的整合方式,或者它们可能与宿主蛋白质相互作用的方式。然而,蛋白质很少单独起作用,大多数生物过程都依赖于与其他蛋白质的相互作用。因此,蛋白质-蛋白质相互作用(PPI)网络为下一代药物靶点提供了一个尚未开发的潜在领域。在这篇综述中,我们认为细菌或宿主-病原体蛋白质互作组的结构可以为新型抗菌药物靶点的识别提供宝贵的见解。